A Phase 2, Multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin Administered for 48 Weeks in Patients Infected With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Phase of Trial: Phase II
Latest Information Update: 28 Jul 2016
At a glance
- Drugs Sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 17 Apr 2016 Primary endpoint has been met (Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)) according to results presented at The International Liver Congress™ 2016.
- 17 Apr 2016 Final results presented at The International Liver Congress™ 2016.
- 07 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.